SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

80.95 -5.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

80.35

Max

85.7

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

36.483

60.328

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+1.64% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

427M

4.4B

Ouverture précédente

86.33

Clôture précédente

80.95

Sentiment de l'Actualité

By Acuity

50%

50%

178 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 avr. 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 avr. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 avr. 2026, 22:33 UTC

Résultats

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 avr. 2026, 22:17 UTC

Résultats

PLS Executed Offtake Agreement With Ronbay

23 avr. 2026, 22:17 UTC

Résultats

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 avr. 2026, 22:16 UTC

Résultats

PLS Commences Commissioning of Midstream Demonstration Plant

23 avr. 2026, 22:15 UTC

Résultats

PLS Group Reaffirms FY26 Guidance for All Metrics

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 avr. 2026, 22:13 UTC

Résultats

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:11 UTC

Résultats

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 avr. 2026, 22:10 UTC

Résultats

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 avr. 2026, 22:09 UTC

Résultats

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 avr. 2026, 22:08 UTC

Résultats

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 avr. 2026, 22:04 UTC

Résultats

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 avr. 2026, 21:56 UTC

Market Talk
Résultats

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 avr. 2026, 21:27 UTC

Résultats

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 avr. 2026, 21:25 UTC

Résultats

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 avr. 2026, 21:24 UTC

Résultats

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 avr. 2026, 21:24 UTC

Résultats

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 avr. 2026, 21:21 UTC

Résultats

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 avr. 2026, 21:21 UTC

Résultats

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

1.64% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  1.64%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

178 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat